Gujarat Exclusive >

Bharat Biotech

More doors open for Covaxin; UK to allow fully vaccinated travellers from November 22

New Delhi: The emergency approval to Covaxin by the World Health Organization (WHO) has opened more doors for those who have received the vaccine. After the United States, now the United Kingdom (UK) too has given the nod to Bharat Biotech’s indigenously developed Covid-19 vaccine. Thus, those who have received both the shots of Covaxin...

After WHO approval, US to allow fully ‘Covaxin-ated’ travellers from November 8

New Delhi: The approval by the World Health Organization (WHO) for India’s indigenous Covid-19 vaccine Covaxin for emergency use has ended the uncertainty among those who had got both doses of the vaccine but were unable to travel in absence of the approval. Bharat Biotech’s Covaxin got the WHO approval on Wednesday. Following this, the...

Fully ‘Covaxin-ated’, but want Covishield to travel abroad? Let’s wait for WHO decision, says SC

New Delhi: The delayed approval to Bharat Biotech’s Covid-19 vaccine Covaxin by the World Health Organization (WHO) has meant many an anxious moment for several individuals who have received it and are unable to travel to certain countries because of lack of approval to Covaxin. A petition in the Supreme Court had sought permission for...

Received Hungary’s GMP certificate for Covaxin: Bharat Biotech

Mumbai: Bharat Biotech said on Thursday that its Covid-19 vaccine Covaxin has received the ‘Good Manufacturing Practices’ (GMP) compliance certificate from Hungary. “Another milestone in our account as COVAXIN® receives GMP certificate from Hungary. This marks the 1st EUDRAGDMP compliance certificate received by Bharat Biotech from European regulatories,” the...

Covaxin clinical trials in Brazil suspended after Bharat Biotech terminates deal

Mumbai: The Brazilian government has announced suspension of clinical trials of Bharat Biotech’s Covid-19 vaccine Covaxin. The development comes a day after the Indian manufacturer announced cancellation of a deal with its partner in Brazil for supply of the vaccine to the South American country. Bharat Biotech had partnered with Brazil’s Precisa for the sale....

Brazil suspends Covaxin deal worth $324 million over allegations of irregularities

As per the deal, Bharat Biotech was to supply 20 million doses of the Covid-19 vaccine Brasilia: In wake of allegations of irregularities, the Brazilian government has suspended a $324 million contract with Bharat Biotech for purchase of its Covid-19 vaccine ‘Covaxin’. The deal for purchase of 20 million doses of the vaccine had been...

Top US institute says Covaxin effective against Delta variant

The US National Institute of Health (NIH) has said that Bharat’s Biotech’s vaccine against COVID-19 ‘Covaxin’ effectively neutralizes the Alpha and Delta variants of coronavirus. The NIH statement is based on two studies. It said the results of two studies of blood serum from people who had received Covaxin suggests that the vaccine generates antibodies...

‘Not paid a cent’: Brazil president Bolsonaro clarifies amid controversy over Covaxin deal

Brasilia: Amid the ongoing controversy over purchase of India-made Covaxin by Brazil, the country’s President Jair Bolsonaro has said that no money has been paid for and no receipt made of the vaccine. The controversy relates to a contract signed by Brazil for 20 million doses of Bharat Biotech’s Covaxin, worth $320 milion. The prosecutor-general’s...

Covaxin found 77.8% effective in protecting against COVID-19 in phase 3 trials

Hyderabad-based vaccine maker Bharat Biotech’s COVID-19 vaccine ‘Covaxin’ has been found to be 77.8 per cent effective in protecting against the viral infection, according to the phase 3 clinical trial results that have been submitted to the Drugs Controller General of India (DCGI). The phase 3 trial involved 25,800 participants from across the country. The...

Bharat Biotech submits Covaxin’s Phase 3 clinical trial data to DCGI

Vaccine maker Bharat Biotech has submitted the third phase clinical trial data of its vaccine against COVID-19 ‘Covaxin’ to the Drugs Controller General of India (DCGI). The subject expert committee of the regulator is going to meet today to deliberate on the data submitted by the company. On Wednesday, the company is supposed to hold...

Bharat Biotech says supplying Covaxin to govt for Rs 150 per dose not sustainable

With the Centre likely to start procuring 75% of the doses of COVID-19 vaccines manufactured in the country for the national vaccination drive, Covaxin maker Bharat Biotech on Tuesday said that supplying the jabs to the government at Rs 150 per dose is not sustainable in the long run. The company is demanding freedom to...

Covaxin’s US approval gets delayed as FDA seeks more data

In a major blow to Bharat Biotech that manufactures the COVID-19 vaccine ‘Covaxin’, the US Food and Drug Administration (FDA) has asked the vaccine maker’s US partner, Ocugen, to go for the lengthier biologics license application (BLA) route and submit additional data. The development has put an end to the company’s hope of getting an...